Literature DB >> 21699136

Selectivity of kinase inhibitor fragments.

Paul Bamborough1, Murray J Brown, John A Christopher, Chun-wa Chung, Geoff W Mellor.   

Abstract

A kinase-focused screening set of fragments has been assembled and has proved successful for the discovery of ligand-efficient hits against many targets. Here we present some of our general conclusions from this exercise. Notably, we present the first profiling results for literature fragments that have previously been used as starting points for optimization against individual kinases. We consider the importance of screening format and the extent to which selectivity is helpful in selecting fragments for progression. Results are also outlined for fragments targeting the DFG-out conformation and for atypical kinases such as PIM1 and lipid kinases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21699136     DOI: 10.1021/jm200349b

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  18 in total

1.  Fragment-Based Discovery of Potent and Selective DDR1/2 Inhibitors.

Authors:  Christopher W Murray; Valerio Berdini; Ildiko M Buck; Maria E Carr; Anne Cleasby; Joseph E Coyle; Jayne E Curry; James E H Day; Phillip J Day; Keisha Hearn; Aman Iqbal; Lydia Y W Lee; Vanessa Martins; Paul N Mortenson; Joanne M Munck; Lee W Page; Sahil Patel; Susan Roomans; Kirsten Smith; Emiliano Tamanini; Gordon Saxty
Journal:  ACS Med Chem Lett       Date:  2015-06-04       Impact factor: 4.345

2.  Facile synthesis of borofragments and their evaluation in activity-based protein profiling.

Authors:  Shinya Adachi; Armand B Cognetta; Micah J Niphakis; Zhi He; Adam Zajdlik; Jeffrey D St Denis; Conor C G Scully; Benjamin F Cravatt; Andrei K Yudin
Journal:  Chem Commun (Camb)       Date:  2015-02-28       Impact factor: 6.222

3.  Extraction and validation of substructure profiles for enriching compound libraries.

Authors:  Wee Kiang Yeo; Mei Lin Go; Shahul Nilar
Journal:  J Comput Aided Mol Des       Date:  2012-09-16       Impact factor: 3.686

4.  Natural-product-derived fragments for fragment-based ligand discovery.

Authors:  Björn Over; Stefan Wetzel; Christian Grütter; Yasushi Nakai; Steffen Renner; Daniel Rauh; Herbert Waldmann
Journal:  Nat Chem       Date:  2012-12-02       Impact factor: 24.427

Review 5.  Twenty years on: the impact of fragments on drug discovery.

Authors:  Daniel A Erlanson; Stephen W Fesik; Roderick E Hubbard; Wolfgang Jahnke; Harren Jhoti
Journal:  Nat Rev Drug Discov       Date:  2016-07-15       Impact factor: 84.694

6.  Electrophilic fragment-based design of reversible covalent kinase inhibitors.

Authors:  Rand M Miller; Ville O Paavilainen; Shyam Krishnan; Iana M Serafimova; Jack Taunton
Journal:  J Am Chem Soc       Date:  2013-03-29       Impact factor: 15.419

7.  Identification of a Novel and Selective Series of Itk Inhibitors via a Template-Hopping Strategy.

Authors:  Catherine M Alder; Martin Ambler; Amanda J Campbell; Aurelie C Champigny; Angela M Deakin; John D Harling; Carol A Harris; Tim Longstaff; Sean Lynn; Aoife C Maxwell; Chris J Mooney; Callum Scullion; Onkar M P Singh; Ian E D Smith; Donald O Somers; Christopher J Tame; Gareth Wayne; Caroline Wilson; James M Woolven
Journal:  ACS Med Chem Lett       Date:  2013-08-12       Impact factor: 4.345

8.  Testing the promiscuity of commercial kinase inhibitors against the AGC kinase group using a split-luciferase screen.

Authors:  Benjamin W Jester; Alicia Gaj; Carolyn D Shomin; Kurt J Cox; Indraneel Ghosh
Journal:  J Med Chem       Date:  2012-02-10       Impact factor: 7.446

9.  Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3.

Authors:  Val S Goodfellow; Colin J Loweth; Satheesh B Ravula; Torsten Wiemann; Thong Nguyen; Yang Xu; Daniel E Todd; David Sheppard; Scott Pollack; Oksana Polesskaya; Daniel F Marker; Stephen Dewhurst; Harris A Gelbard
Journal:  J Med Chem       Date:  2013-10-03       Impact factor: 7.446

10.  Crystal structures of ASK1-inhibtor complexes provide a platform for structure-based drug design.

Authors:  Onkar Singh; Anthony Shillings; Peter Craggs; Ian Wall; Paul Rowland; Tadeusz Skarzynski; Clare I Hobbs; Phil Hardwick; Rob Tanner; Michelle Blunt; David R Witty; Kathrine J Smith
Journal:  Protein Sci       Date:  2013-07-03       Impact factor: 6.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.